Suppr超能文献

多系统萎缩的神经病理学及其治疗意义。

The neuropathology of multiple system atrophy and its therapeutic implications.

作者信息

Valera Elvira, Masliah Eliezer

机构信息

Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Division of Neurosciences, National Institute on Aging/NIH, 7201 Wisconsin Ave, Bethesda, MD 20814, USA.

出版信息

Auton Neurosci. 2018 May;211:1-6. doi: 10.1016/j.autneu.2017.11.002. Epub 2017 Nov 10.

Abstract

Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by the abnormal accumulation of toxic forms of the synaptic protein alpha-synuclein (α-syn) within oligodendrocytes and neurons. The presence of α-syn within oligodendrocytes in the form of glial cytoplasmic inclusions is the diagnostic hallmark of MSA. However, it has been postulated that α-syn is produced in neurons and propagates to oligodendrocytes, where unknown mechanisms lead to its accumulation. The presence of α-syn within neurons in MSA has not been so extensively studied, but it may shed light into neuropathological mechanisms leading to oligodendroglial accumulation. Here we summarize the principal neuropathological events of MSA, and discuss how a deeper knowledge of these mechanisms may help develop effective therapies targeting α-syn accumulation and spreading.

摘要

多系统萎缩(MSA)是一种致命的神经退行性疾病,其特征是突触蛋白α-突触核蛋白(α-syn)的毒性形式在少突胶质细胞和神经元内异常积聚。少突胶质细胞内以胶质细胞质内含物形式存在的α-syn是MSA的诊断标志。然而,据推测α-syn在神经元中产生并传播到少突胶质细胞,在少突胶质细胞中未知机制导致其积聚。MSA中神经元内α-syn的存在尚未得到如此广泛的研究,但它可能有助于揭示导致少突胶质细胞积聚的神经病理机制。在这里,我们总结了MSA的主要神经病理事件,并讨论了对这些机制的更深入了解如何有助于开发针对α-syn积聚和扩散的有效疗法。

相似文献

1
The neuropathology of multiple system atrophy and its therapeutic implications.
Auton Neurosci. 2018 May;211:1-6. doi: 10.1016/j.autneu.2017.11.002. Epub 2017 Nov 10.
3
Neuropathology of multiple system atrophy: new thoughts about pathogenesis.
Mov Disord. 2014 Dec;29(14):1720-41. doi: 10.1002/mds.26052. Epub 2014 Oct 9.
6
The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy.
Biochim Biophys Acta Mol Basis Dis. 2019 Nov 1;1865(11):165513. doi: 10.1016/j.bbadis.2019.07.007. Epub 2019 Jul 16.
7
Oligodendroglial α-synucleinopathy-driven neuroinflammation in multiple system atrophy.
Brain Pathol. 2019 May;29(3):380-396. doi: 10.1111/bpa.12678. Epub 2019 Jan 31.
8
Review: Multiple system atrophy: emerging targets for interventional therapies.
Neuropathol Appl Neurobiol. 2016 Feb;42(1):20-32. doi: 10.1111/nan.12304.
9
SNCA and TPPP transcripts increase in oligodendroglial cytoplasmic inclusions in multiple system atrophy.
Neurobiol Dis. 2024 Aug;198:106551. doi: 10.1016/j.nbd.2024.106551. Epub 2024 Jun 3.
10
Multiple system atrophy: α-Synuclein strains at the neuron-oligodendrocyte crossroad.
Mol Neurodegener. 2022 Nov 26;17(1):77. doi: 10.1186/s13024-022-00579-z.

引用本文的文献

1
Gradients of Nigrostriatal Iron Deposition in Healthy Aging and Synucleinopathies.
CNS Neurosci Ther. 2025 Mar;31(3):e70359. doi: 10.1111/cns.70359.
3
Toward a biological definition of neuronal and glial synucleinopathies.
Nat Med. 2025 Feb;31(2):396-408. doi: 10.1038/s41591-024-03469-7. Epub 2025 Jan 30.
6
Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials.
J Neurol. 2024 May;271(5):2324-2344. doi: 10.1007/s00415-024-12269-5. Epub 2024 Mar 14.
7
Distinct forebrain regions define a dichotomous astrocytic profile in multiple system atrophy.
Acta Neuropathol Commun. 2024 Jan 2;12(1):1. doi: 10.1186/s40478-023-01699-3.
8
Ultrastructures of α-Synuclein Filaments in Synucleinopathy Brains and Experimental Models.
J Mov Disord. 2024 Jan;17(1):15-29. doi: 10.14802/jmd.23213. Epub 2023 Nov 22.
9
Multiple system atrophy - a clinicopathological update.
Free Neuropathol. 2020 Jul 3;1:17. doi: 10.17879/freeneuropathology-2020-2813. eCollection 2020 Jan.

本文引用的文献

1
Therapeutic approaches to target alpha-synuclein pathology.
Exp Neurol. 2017 Dec;298(Pt B):225-235. doi: 10.1016/j.expneurol.2017.10.003. Epub 2017 Oct 4.
3
First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.
Mov Disord. 2017 Feb;32(2):211-218. doi: 10.1002/mds.26878. Epub 2016 Nov 25.
4
A genome-wide association study in multiple system atrophy.
Neurology. 2016 Oct 11;87(15):1591-1598. doi: 10.1212/WNL.0000000000003221. Epub 2016 Sep 14.
5
Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy.
Neurotherapeutics. 2016 Oct;13(4):871-879. doi: 10.1007/s13311-016-0447-1.
6
α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy.
Acta Neuropathol. 2016 Jul;132(1):59-75. doi: 10.1007/s00401-016-1572-y. Epub 2016 Apr 8.
7
Review: Multiple system atrophy: emerging targets for interventional therapies.
Neuropathol Appl Neurobiol. 2016 Feb;42(1):20-32. doi: 10.1111/nan.12304.
8
Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation.
Front Cell Neurosci. 2015 Nov 12;9:437. doi: 10.3389/fncel.2015.00437. eCollection 2015.
9
Combination therapies: The next logical Step for the treatment of synucleinopathies?
Mov Disord. 2016 Feb;31(2):225-34. doi: 10.1002/mds.26428. Epub 2015 Sep 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验